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The adaptive immune system of cartilaginous fish (Elasmobranchii), comprising of classical 31 
hetero-tetrameric antibodies, is enhanced through the presence of a naturally occurring 32 
homodimeric antibody-like immunoglobulin - the new antigen receptor (IgNAR). The binding-33 
site of the IgNAR variable single-domain (VNAR) offers advantages of reduced size (<1/10th 34 
of classical immunoglobulin) and extended binding topographies, making it an ideal candidate 35 
for accessing cryptic epitopes otherwise intractable to conventional antibodies. These 36 
attributes, coupled with high physicochemical stability and amenability to phage display, 37 
facilitates selection of VNAR binders to challenging targets. Here, we explored the unique 38 
attributes of these single-domains for potential application as bioprocessing reagents in the 39 
development of the SEED-Fc platform, designed to generate therapeutic bispecific antibodies.  40 
A panel of unique VNARs specific to the SEED homodimeric (monospecific) “by-products” 41 
were isolated from a shark semi-synthetic VNAR library via phage display. The lead VNAR 42 
candidate exhibited low nanomolar affinity and superior selectivity to SEED homodimer, with 43 
functionality being retained upon exposure to extreme physicochemical conditions that mimic 44 
their applicability as purification agents. Ultimately, this work exemplifies the robustness of 45 
the semi-synthetic VNAR platform, the predisposition of the VNAR paratope to recognise 46 
novel epitopes, and the potential for routine generation of tailor-made VNAR-based 47 
bioprocessing reagents. 48 
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The plethora of bispecific antibody (bsAb) formats currently in development (Spiess et al. 62 
2015; Brinkmann and Kontermann 2017) typifies the heightened interest in these next-63 
generation biotherapeutics. In turn, this expanding multitude of bsAbs necessitates robust 64 
manufacturing platforms for their unhindered progress into clinical use and on hopefully to 65 
deliver both patient and commercial benefits (Liu et al. 2017; Shukla et al. 2017). High 66 
expression yield is not necessarily the single most important factor for these formats, but rather 67 
the efficiency with which the bsAbs form, and the corresponding presence of closely related 68 
but contaminating by-products of the processes employed (e.g. monospecific binders) 69 
(Brinkmann and Kontermann 2017). One molecular route to bsAbs is based on a heterodimeric 70 
Fc engineering approach, to generate asymmetric mutations in each of two parental mAb CH3 71 
domains (Ha et al. 2016).  This is employed in the strand-exchange engineered domain (SEED) 72 
Fc platform (Gross et al. 2013), and resolves the majority of the heavy chain mispairing seen 73 
for other systems (Davis et al. 2010; Krah et al. 2017).  This increase in efficiency is in part 74 
the result of the SEED design rationale, incorporating complementary human IgG/IgA Fc 75 
hybrids that are “encouraged” to preferentially heterodimerise, forming an analogue Fc 76 
scaffold (Gross et al. 2013). Whilst the early efficacy data looks very promising, indicating a 77 
favourable pharmacokinetic profile and retention of antibody-like effector functions (Muda et 78 
al. 2011; Kelton et al. 2012), the GA chain can form low-levels of contaminating GA-GA 79 
SEED homodimers (Davis et al. 2010).  Thus far, none of the Fc heterodimeric approaches 80 
have achieved 100% heterodimerisation, with low-levels (1–10%) of mispaired 81 
homodimerisation being seemingly inevitable in large-scale production (Sampei et al. 2013; 82 
Ha et al. 2016; Skegro et al. 2017).  This mixed population of therapeutic scale product 83 
requires, therefore, to be better characterised (or even polished) and quantifiable batch 84 
consistency determined to facilitate efficient downstream bioprocessing and regulatory 85 
approvals (Kufer et al. 2004; Ha et al. 2016).  86 
To date, the main efforts employed to resolve this bioprocessing bottleneck have been 87 
focussed on improving the manufacturability of bsAbs by further rounds of molecular 88 
engineering (Sampei et al. 2013; Skegro et al. 2017).  At the same time, advances in upstream 89 
monoclonal antibody (mAb) processing has led to significant improvements in production 90 
yields, placing even greater cost pressures on finding a suitable solution to the presence of 91 
monospecific binders in the bispecific therapeutic programs (Girard et al. 2015).  92 
For the generation of a generic approach that would work for all SEED systems the 93 
recognition and/or purification challenge is not straightforward because of the close structural 94 
and physicochemical resemblance of the desired heterodimeric bsAb with the by-product 95 
homodimers. With only a small number of subtle differences between them in their Fc regions 96 
(Shukla and Norman 2017) these changes cannot be distinguished by conventional protein A 97 
capture, resulting in their co-elution (Liu et al. 2017). Alternative purification methods could 98 
use anti-idiotypic ligands specific for intact antibody paratopes (Godar et al. 2015; Könning, 99 
Rhiel et al. 2017).  However elegant, such a dual anti-idiotypic purification process lacks 100 
universal application, requiring an individual selection campaign for each bsAb arm.  101 
Shark-derived single-domains provide opportunities as alternative affinity capture 102 
reagents, sharing many similar properties to VHH domains (Wesolowski et al. 2009; Könning, 103 
Zielonka et al. 2017) but superior when one considers size (up to 20% smaller), stability, and 104 
density of binding loops per domain (with four regions of hypervariability versus VHH’s three) 105 
(Kovaleva et al. 2014).  VNAR’s distinct structural paratope (Diaz et al. 2002; Stanfield et al. 106 
2004), inherent stability (Griffiths et al. 2013, Ubah et al. 2017), amenability to display 107 
technologies (Ubah et al. 2016) and site-specific covalent coupling to crystalline nanocellulose 108 
(Uth et al. 2014), reinforces VNAR’s attractiveness.  109 
VNARs were isolated from a semi-synthetic phage display library through a solution-110 
phase selection technique using biotinylated SEED Fc-based protein [N-terminal IgG1 hinge 111 
region-IgG1 CH2-(SEED CH3)] in the form of ‘the contaminant’ SEED homodimer (Fc-112 
GA/GA-Fc) protein.  A successful “candidate” affinity ligand had to demonstrate superior 113 
selectivity to the target protein present at <1% of the total protein yield (~20–100 µg/mL) 114 
(Davis et al. 2010), with the ability to differentiate between closely related mispaired formats, 115 
and also show efficient elution from the target/ligand complex.  In addition, the VNAR affinity 116 
ligand had to be sufficiently stable to retain activity under harsh bioprocessing conditions, 117 
enabling reusability without compromising performance.  118 
 119 
Materials and methods 120 
Phage display selection 121 
A shark VNAR synthetic library (ELSS1, Elasmogen Ltd., patent WO/2014/173959) of 122 
combined size 1x1011, was selected via a solution-phase method (Hawkins et al. 1992) with 123 
biotinylated SEED Fc homodimer protein: GA-GA Fc (Merck KGaA, Darmstadt Germany) 124 
captured on streptavidin magnetic beads (Dynabeads M-280, Invitrogen). Clearly the purity of 125 
the starting antigens is a key consideration influencing the selection of specific binders.   The 126 
homodimer purity (GA-GA Fc protein) was confirmed with both analytical HPLC, and 127 
isoelectric focusing gel analysis that allows the amino acid composition of the AG and GA 128 
SEED chains to be distinguished using different isoelectric point (pI) values (theoretical pI 129 
values: AG=8.2; GA=6.4; AG/GA=7.3) (Gross et al. 2013).   Using these approaches in 130 
combination the protein was determined to be pure.  For the purpose of solution-phase 131 
selection, the SEED protein was biotinylated via EZ-Link Sulfo-NHS-LC-Biotin kit (Thermo 132 
Scientific). Phage display library selections were performed using >1013 phage/mL. Library 133 
phage and Dynabeads (2x 100 µL) were blocked with 3% (w/v) Marvel milk proteins in 1x 134 
PBS (MPBS) for 1 h, rotating at room temperature. Phage were deselected on blocked beads, 135 
while the remaining beads were incubated with biotinylated-SEED homodimer (200 nM) for 1 136 
h rotating at room temperature. SEED pre-decorated beads were then incubated with deselected 137 
phage for a further 1 h.  Wash stringency was maintained at five times 1x PBS-0.05% (v/v) 138 
Tween20 (PBST) and five 1x PBS, prior to an 8 min elution with 200 μL of 100 mM 139 
triethylamine, and neutralisation with 100 μL of 1 M Tris-HCl, pH 7.5. Eluted phage output 140 
was amplified through infection of 10 mL mid-log phase Escherichia coli (E. coli) TG1 cells 141 
(Lucigen) for 30 min (static), at 37°C. Following infection, the cells were concentrated by 142 
centrifugation, and plated on TYE agar bioassay plate containing 2% (w/v) glucose and 100 143 
μg/mL ampicillin. The phage selection output was rescued according to a previously described 144 
protocol by Dooley et al. 2003. In brief, the selection output was scraped-off the bioassay agar 145 
plate and seeded into 50 mL of 2xTY, 2% (w/v) glucose, 100 µg/mL ampicillin media at 146 
OD600 of 0.1, and grown at 37oC 250 rpm to OD600 of ~0.5. The selected phage were rescued 147 
by infecting the culture with M13K07 helper phage (New England Biolabs) at 20:1 ratio 148 
(phage:cells) and incubated for 30 min (static) at 37°C, followed by 1 h shaking at 150 rpm. 149 
The cells were pelleted and re-suspended in 50 mL of 2xTY media containing 100 μg/mL 150 
ampicillin and 50 μg/mL kanamycin prior to overnight incubation at 25°C, 250 rpm shaking.   151 
Phage-VNAR particles were concentrated from the culture supernatant by two successive 152 
precipitations with 1/5th volume of ice-cold 20% (w/v) polyethylene glycol/2.5 M NaCl with 153 
30 min incubation on ice.  The resulting precipitated phage were used as the input phage for 154 
the next round of selection, with two further rounds of selection being carried out and 155 
stringency being increased by a successive 2-fold reduction in biotinylated-SEED homodimer 156 
concentration.  157 
Screening of SEED homodimer specific binders  158 
The enrichment of antigen-binding clones was evaluated via monoclonal phage enzyme-linked 159 
immunosorbent assay (ELISA). Ninety-two individual colonies were picked from each 160 
selection round and screened for binding specificity to SEED protein: GA-GA Fc homodimer, 161 
AG-GA Fc heterodimer, and an unrelated human serum albumin (HSA) protein control 162 
(Sigma-Aldrich), coated onto MaxiSorp ELISA plates (Thermo Fisher Scientific) at 1 μg/mL 163 
in 1x PBS, 4°C overnight.  Monoclonal phages were inoculated from overnight starter cultures 164 
into 96-deep-well plates (Greiner Bio-One) with 800 μL/well 2xTY, 2% (w/v) glucose, 100 165 
µg/mL ampicillin media, and grown with shaking at 37°C for 4 h. The phage-VNAR particles 166 
were rescued by infection with M13K07 helper phage and two successive precipitations with 167 
polyethylene glycol/2.5 M NaCl, as described above. Precipitated phage was added to ELISA 168 
plates pre-blocked with 3% MPBS and incubated for 1 h at room temperature. Phage signals 169 
were detected via horseradish peroxidase (HRP)-conjugated anti-M13 antibody (GE 170 
Healthcare, 27-9421-01) diluted 1/1,000 in 3% MPBS for 1 h at room temperature. ELISA was 171 
developed with 3,3',5,5'-tetramethylbenzidine substrate (Thermo Fisher Scientific) for 10 min 172 
at room temperature and stopped with 0.5 volume of 1 M H2SO4, and the optical density (OD) 173 
was measured at 450 nm. Plasmid DNA was prepared from antigen binding clones via 174 
Wizard® Plus SV Minipreps DNA Purification System (Promega) for sequencing (GATC 175 
Biotech). 176 
Preparation of soluble VNAR proteins 177 
Anti-SEED VNAR binders were rescued with M13K07 helper phage, and the supernatant was 178 
used to infect mid-log phase HB2151 cells (a kind gift from Scotia Biologics Ltd.) for 30 min 179 
at 37°C static. VNAR proteins were expressed in the cytoplasm of HB2151 cells at 1 litre scale. 180 
Day cultures (TB media with 2% glucose and 100 µg/mL ampicillin) were seeded from 181 
overnights at 1:50 dilution and grown for 7 h at 37°C, pellets were re-suspended in the same 182 
culture volume (minus glucose) with a final concentration of 1 mM isopropyl β-D-1-183 
thiogalactopyranoside (Sigma-Aldrich) at 15°C overnight, with shaking. Cells were harvested, 184 
and pellets treated with a 10% culture volume of ice-cold osmotic shock buffer: 200 mM Tris-185 
HCl, 1 mM EDTA, 20% (w/v) sucrose, pH 7.4, shaking on ice for 15 min, prior to an equal 186 
volume of ice-cold 5 mM MgSO4 then added with continued shaking for a further 15 min. The 187 
supernatant was recovered containing the periplasmic extract. The VNAR soluble protein was 188 
purified via its hexa-histidine tail using nickel ion charged immobilised metal affinity 189 
chromatography agarose (Qiagen), and eluted with 500 mM imidazole, pH 8.0. Protein samples 190 
were dialysed against 1x PBS, pH 7.4, before use. Protein concentration and purity was 191 
determined by SDS-PAGE. 192 
Determination of binding selectivity and affinity 193 
The binding selectivity of purified VNARs was determined on ELISA plates coated with a 194 
range of proteins at 1 μg/mL: both forms of SEED protein, HSA, analogue Fc scaffolds (Sigma-195 
Aldrich) in 1x PBS, 100 μL/well, overnight at 4°C, followed by 1 h blocking at room 196 
temperature in 3% MPBS, 200 μL/well. Purified VNARs were added at a top concentration of 197 
2.5 µg/mL and serial dilutions performed, incubated at room temperature for 1 h. The bound 198 
VNARs were detected using an anti-c-Myc-HRP antibody (Roche, 11814150001).  199 
Binding affinities were determined by surface plasmon resonance on a BIAcoreTM T200 200 
(GE Healthcare).  SEED protein was immobilised onto a CM5 Series S chip (GE Healthcare) 201 
in 10 mM sodium acetate pH 5.5 via an amine coupling kit (GE Healthcare) giving a coating 202 
density of approximately 1,000 RU. A blank immobilisation was carried out for reference 203 
subtraction. The purified VNAR protein was diluted in running buffer (10 mM HEPES, 500 204 
mM NaCl, 0.05% Tween20, pH 7.4) to 60, 30, 15, 8, 4 and 2 nM. Each concentration was 205 
injected over the immobilised ligand for 5 min at a flow rate of 30 μL/min, 20°C, and allowed 206 
to dissociate for 10 min, followed by a 0.5 min regeneration with 20 mM glycine-HCl, pH 1.7. 207 
The resultant sensorgrams were analysed using BIAcoreTM evaluation software. 208 
For the selectivity assessment on BIAcoreTM T200, the VNAR F3 monomer was 209 
immobilised via amine coupling on the chip surface Fc2, giving a coating density of 200 RU. 210 
The flow channel Fc1 was used as a reference flow channel. In the interaction assay, different 211 
homodimer and heterodimer concentrations present in solution were injected over the 212 
immobilised ligand, and regenerated with glycine-HCl, pH 1.5. 213 
Determination of VNAR stability  214 
Thermal stability analysis was conducted using an ELISA format following published methods 215 
(Dooley et al. 2003; Shao et al. 2007). To assess VNAR’s ability to withstand irreversible 216 
thermal denaturation, soluble VNAR protein samples at 10 µg/mL working concentration were 217 
incubated for 1 h at a range of temperatures (25–100°C) on a gradient thermocycler. Following 218 
heat treatment samples were allowed to cool to room temperature before analysis of binding 219 
activity in an ELISA coated with SEED homodimer at 1 µg/mL. ELISA was performed using 220 
1 µg/mL final concentration of VNAR protein, which was serially diluted. Residual binding 221 
activity was detected with an anti-c-Myc-HRP antibody (Roche, 11814150001) and expressed 222 
as a percentage of the OD value of untreated controls.  223 
Similarly, pH stability of VNAR domains was determined by ELISA plates coated with 224 
SEED homodimer at 1 µg/mL. VNAR proteins were prepared at a working stock of 20 µg/mL 225 
in a final volume of 50 µL in 0.1 M glycine-HCl (G-HCl) at designated pH values ranging from 226 
1.5-8.0. Following overnight incubation at room temperature, aliquots were withdrawn and 227 
neutralised in 1x PBS (pH 7.4) to a final concentration of 1 µg/mL directly in an ELISA plate 228 
and serially diluted. Active protein was detected as above. 229 
A thermal shift assay, to determine VNAR’s melting temperature (Tm) and structural 230 
stability of the domains, was conducted (Liu et al. 2014).  This fluorescence-based melting 231 
assay made use of a StepOnePlus™ Thermocycler (Applied Biosystems) and SYPRO® 232 
Orange fluorophore (Sigma-Aldrich Corp.) at a final dilution of 1:1,000 and a total of 10 µg 233 
VNAR protein in a 50 µL reaction volume triplicate, prepared in 1x PBS, pH 7.4. The 234 
temperature was increased from 25°C to 80°C at ∼2°C/min. Tm values were obtained from 235 
melting curves using the corresponding Protein Thermal Shift analysis software.  236 
Assessing VNAR’s applicability as a detection reagent 237 
A sandwich ELISA format was applied to test the ability of lead VNAR F3 to detect SEED 238 
homodimer present in solution, mimicking intended application as a bioprocessing reagent. 239 
ELISA plate was coated overnight at 4°C with the VNAR protein as a capture ligand at 2.5 240 
µg/mL in 1x PBS, 100 µL/well. SEED protein was added at top concentration of 10 µg/mL 241 
and serially diluted in 1x PBS, incubated for 1 h at room temperature. Binding was detected 242 
indirectly with 1/1,000 dilution of goat anti-human IgG (Fc specific) antibody (Sigma-Aldrich, 243 
2136) and rabbit anti-goat IgG-HRP (Sigma-Aldrich, A8919). 244 
The VNAR proteins were further evaluated for their applicability as detection reagents 245 
capturing target from a heterogeneous mix of SEED proteins in solution. VNARs were 246 
immobilised on an ELISA plate at a sub-saturating concentration in 1x PBS, 100 µL/well, 247 
incubated overnight at 4°C. SEED proteins were pre-mixed at different proportions of 248 
homodimer and heterodimer in a final combined concentration of 5 µg/mL prior to their 249 
addition to a blocked ELISA plate at 100 µL/well in duplicate, then incubated for 1 h at room 250 
temperature and washed as standard.  Binding signal was generated following standard 251 
protocols and via detection of bound SEED protein with a 1/200 dilution of anti-human IgG 252 
(Fc specific)-HRP antibody (Sigma-Aldrich, A0170).  253 
Bio-layer interferometry analysis 254 
Determination of VNAR’s applicability as a detection reagent to screen and quantify 255 
contaminating levels of SEED homodimer (GA/GA) protein was performed on the Octet® QK 256 
System (Pall FortéBio) with Octet Data Acquisition software 7.0. Binding association was 257 
measured in 100 µL/well 1x PBS at 30°C with 1,000 rpm orbital agitation using 96-well half-258 
area black microplates (Greiner Bio-One). Anti-mouse IgG Fc capture (AMC) Dip and Read™ 259 
biosensors (Pall FortéBio) were pre-equilibrated in 1x PBS, pH 7.4, for 10 min. Subsequently, 260 
recombinant VNAR protein containing a C-terminal-mouse IgG2a Fc fusion was loaded onto 261 
biosensor tips at a concentration of 80 µg/mL for 200 s. Followed by 60 s wash in 1x PBS.  262 
Association was performed using SEED homodimer (GA/GA) Fc protein at 150 µg/mL and 75 263 
µg/mL for 100 s.  264 
pH elution ELISA  265 
An ELISA-elution assay was adapted from (Kummer and Li-Chan 1998), as a screening tool 266 
to test the dissociation of the VNAR-SEED complex and to compare the effectiveness of 267 
eluents. ELISA plates were coated with F3 VNAR protein at 2.5 μg/mL in 1x PBS, 100 μL/well 268 
overnight at 4°C. A total of 100 μL of SEED homodimer protein at a concentration of 5 μg/mL 269 
in 1x PBS was applied to the wells and incubated at room temperature for 1 h. The eluent used 270 
in this study was 0.1 M glycine-HCl (G-HCl), which is a standard eluent for IgG purification, 271 
and the effectiveness of a range of pH 1.5–8.0 on dissociation was assessed. Each elution buffer 272 
was applied at a volume of 100 μL/well: once, twice or three times, with incubation periods at 273 
room temperature of 20 min each. The SEED protein remaining after elution was detected 274 
indirectly with anti-human IgG (Fc specific) (Sigma-Aldrich, I2136) and anti-goat-HRP 275 
(Sigma-Aldrich, A8919) conjugate diluted 1/1,000 in 3% MPBS. The potential denaturing 276 
effects of the eluents were also monitored, where the integrity of the VNAR was examined by 277 
testing subsequent re-binding to SEED homodimer protein.  278 
Site-directed biotinylation of VNAR domains 279 
For the purpose of site-directed biotinylation of VNAR F3 monomer, commercially available 280 
Expresso® Biotin Cloning and Expression System (Lucigen) was used as per manufacturer’s 281 
instructions. To evaluate the capture of SEED protein from solution, biotinylated VNAR F3 282 
protein was immobilised on streptavidin magnetic Dynabeads M-280 for 30 min at room 283 
temperature, rotating at 20 rpm. The depleted supernatant was collected through magnetic rack 284 
pull-down and the beads were washed with 1 mL 1x PBS, upon which 50 µL of 100 µg/mL 285 
SEED protein either homodimer or heterodimer was added to the pelleted beads for re-286 
suspension and incubated for 1 h at room temperature, rotating at 20 rpm. Finally, the 287 
supernatant was collected by pelleting the beads on a magnetic rack, and re-suspending the 288 
beads in 50 µL 1x PBS. Both supernatant and beads were reduced and analysed on SDS-PAGE, 289 
and Western blot via anti-human IgG (Fc specific)-HRP (Sigma-Aldrich, A0170) (1:1,000 290 
dilution) to detect captured SEED protein. 291 
Reformatting and transient expression of VNAR as Fc fusion 292 
Plasmid DNA encoding VNAR F3 was isolated via Wizard® Plus SV Minipreps DNA 293 
Purification System (Promega), cloned into pEEE2A mouse IgG2a Fc vector (Elasmogen Ltd.) 294 
through restriction BssHII and BsiWI cloning and transformed into electrocompetent E. coli 295 
XL1-Blue cells (Agilent Technologies). Once the DNA sequence was confirmed, plasmid 296 
DNA from individual clones was extracted via Qiagen Plasmid Midi Kit for PEI-mediated 297 
transfection and transient expression in HEK293 host cells (Huh et al. 2007; Backliwal et al. 298 
2008) using serum free FreeStyle™ 293 media (Invitrogen). Purification of expressed protein 299 
was achieved by protein A affinity chromatography (ProSep Ultra Plus Protein A, Millipore). 300 
To the harvested supernatant, 1/10th volume of 1 M Tris-HCl buffer (pH 8.0) and 5 M NaCl 301 
was added and mixed thoroughly before adding 1.5 mL protein A resin per 100 mL culture. 302 
The suspension was kept rotating at 15 rpm for 3 h at room temperature. The resulting resin 303 
was washed 3x with 1x PBS and loaded onto gravity flow Poly-Prep® columns (Bio-Rad 304 
Laboratories). VNAR-Fc fusion protein was eluted using 8 mL 0.1 M G-HCl buffer, pH 3.0, 305 
and the eluate neutralised with 2 mL 1 M Tris-HCl buffer, pH 8.0. The eluate was buffer 306 
exchanged into 1x PBS through dialysis (Snake Skin® dialysis tubing 7 kDa MWCO, Thermo 307 
Fisher Scientific) against 1 L 1x PBS/1 mL eluted protein, pH 7.4, overnight at 15ºC, followed 308 
by further 5 h dialysis in fresh 1x PBS and finally concentrated using Amicon® Ultra-15 309 
Centrifugal Filters (MWCO 10 kDa). Protein quality was assessed via SDS-PAGE and 310 
quantified using Ultrospec™ 6300 pro UV/Visible Spectrophotometer (Amersham Bioscience) 311 
taking an absorbance reading at 280 nm wavelength.  312 
For kinetic analysis of VNAR fusions, SEED ligand was immobilised at approximately 313 
1,000 RU on a CM5 series S chip in 10 mM sodium acetate, pH 5.5. The purified F3-Fc fusion 314 
protein and the F3 monomer were diluted separately in running buffer to final concentrations 315 
of 250, 125, 62.5, 31.25, 15.63, 7.82, 3.91, 1.95 and 0 nM at 25°C. Each concentration was 316 
injected over immobilised ligand for 5 min at a constant flow rate of 30 μL/min and allowed to 317 
dissociate for 10 min, followed by a 30 s regeneration pulse with 20 mM glycine, pH 1.7, at 30 318 
μL/min, 240 s stabilisation period and a 50 mM NaOH wash. Reference subtracted sensorgrams 319 
for each concentration were analysed. 320 
Results  321 
Selection of single-domains specific to SEED homodimer 322 
With the aim of isolating antigen-specific shark-derived single-domain binders via phage 323 
display, a synthetic VNAR phage library ELSS1 (Elasmogen Ltd., patent WO/2014/173959) 324 
was panned against biotinylated SEED target captured on streptavidin magnetic beads. The 325 
method of antigen presentation was a key influencer on the selection outcome.  To more closely 326 
mimic natural target presentation (Verheesen et al. 2003) this solution-based method biased 327 
outcomes towards the isolation of binders to soluble forms of the target proteins. Three rounds 328 
of affinity selections were carried out against SEED homodimer target, with a 2-fold reduction 329 
in antigen concentration from round 2 included, to help drive the isolation of target specific 330 
high-affinity binders. Enrichment was evaluated via monoclonal phage ELISA against the 331 
selection target: SEED homodimer and a control protein, HSA. A high proportion of ELISA-332 
positive clones with OD450 nm ≥0.5 (as determined by ELISA cut-off) were isolated after the 333 
third round of selection (Figure 1a). No binding to HSA was observed. Furthermore, individual 334 
clones from round 3 phage were assessed for SEED selectivity by ELISA (Figure 1b), and 335 
specifically their ability to distinguish between the two forms of the SEED protein, homodimer 336 
and heterodimer formats.  337 
Sequence analysis of selected clones 338 
Sequence analysis identified only four unique homodimer-specific leads which may indicate 339 
the rarity of binders capable of distinguishing between two such closely related antigens.  340 
Whilst several hundred clones were screened, only 20 clones (less than 1%) were sequenced 341 
based on their binding profile meeting the following criteria: (i) a “strong” positive (above 0.5 342 
O.D) binding signal via phage ELISA, (ii) confirmatory binding of the same clones after 343 
soluble protein was released (but not purified) from the bacterial periplasm and (iii) negative 344 
on the control heterodimer antigen.   Out of these 20 clones; 4 had frameshifts when sequenced, 345 
F3 appeared 3 times out of the remaining 16 sequences, and C3; 5 out of 16, E4 and A4 346 
appeared once. In total 8 unique clones were identified however the remaining 4 clones were 347 
considered positive but weak binders as soluble protein. 348 
Unique binding sequences were aligned using the clustalW method in MegAlign 349 
DNASTAR Lasergene12 software and deduced amino acid sequences (Figure 2a) with 350 
variations limited to within the CDR1 and CDR3 regions. Interestingly, despite the theoretical 351 
sequence diversity of the synthetic library (100 billion unique clones), two homodimer specific 352 
binders, E4 and C3, shared the same CDR1 sequence. Sequence analysis also established that 353 
these selected VNARs were either of type IIb or IIIb IgNAR genes that lacked non-canonical 354 
cysteines residues and maintained a tryptophan (W) residue in CDR1, typical of type IIIb 355 
isotypes (Kovaleva et al. 2014), and which is a significant proportion of the ELSS1 library. 356 
Canonical cysteines were maintained in frameworks 1 and 3b (Streltsov et al. 2004) to stabilise 357 
the VNAR fold (ribbon representation, Figure 2b). 358 
VNAR characterisation: specificity and affinity  359 
To demonstrate that the lead VNAR domains were capable of selective binding to SEED 360 
homodimer, and also lacked cross-reactivity to analogues Fc scaffolds, the VNAR leads were 361 
expressed as soluble protein to allow functional characterisation in the absence of phage 362 
particles. Recombinant VNARs were harvested from E. coli cell periplasm and purified by 363 
nickel affinity chromatography via the hexa-histidine tail. The specificity of antigen binding 364 
was determined by ELISA via anti-c-Myc-HRP detection.  All four clones showed superior 365 
binding to SEED homodimer with no reactivity to other related Fc domains including: SEED 366 
heterodimer, IgG or IgA from human sera or IgG from sera of other species: mouse, rat, sheep, 367 
rabbit (Figure 3).  368 
The choice of a lead candidate was prioritised on the basis of the greatest affinity and 369 
optimal binding kinetics for the SEED homodimer. Using these criteria, clone F3 was selected 370 
as it exhibited the most favourable binding kinetics, quantified with surface plasmon resonance 371 
analysis by BIAcoreTM (Figure 4), with overall affinity in the low nM range (Table 1).  372 
Evaluation of VNAR domain applicability as diagnostic and purification reagents  373 
SEED selectivity in solution  374 
Recombinant VNARs were tested for their ability to capture SEED in a sandwich ELISA 375 
(Figure 5), with the ELISA set-up mimicking affinity purification (i.e. where VNAR is 376 
immobilised and SEED is present in solution). The F3 clone performed well as a capture 377 
reagent, demonstrating its ability to bind SEED homodimer (Figure 5a) whilst maintaining no 378 
reactivity to the heterodimer analogue (Figure 5b).  379 
VNAR F3 characterisation: stability assessment   380 
A key deliverable from this study was to assess the utility of isolated SEED binders as 381 
(reusable) affinity purification reagents using pH changes to modify elution conditions.  VNAR 382 
F3 could tolerate a wide range of pH 1.5-8.0 using 0.1 M G-HCl eluent (Figure 6a), a crucial 383 
characteristic for the reusability of any purification resin. The ability of purified F3 VNAR 384 
protein to withstand irreversible thermal denaturation during a short (1 h) incubation period at 385 
elevated temperature was also investigated. Upon heat exposure to a range of temperatures, F3 386 
protein was serially diluted and assessed for binding functionality in ELISA. The percentage 387 
binding activity in comparison to controls held at room temperature was calculated and the 388 
values were plotted in Figure 6b. Approximately 90% activity was retained at the top VNAR 389 
concentration up to 50oC, with a progressive drop in activity observed at higher temperatures. 390 
This correlated well with F3’s melting temperature of ~50°C as determined by the thermal shift 391 
assay (Figure 6c).  392 
pH elution efficacy 393 
An ELISA-elution assay was devised as a screening tool for quantifying dissociation efficiency 394 
of the VNAR-antigen complex.  The effect of one, increasing to three, washes with 0.1 M G-395 
HCl as eluent, at a range of pHs from 1.5–8.0 on the dissociation of VNAR F3 bound to SEED 396 
homodimer protein was quantified (Figure 7a). As a control these ELISA absorbance values 397 
were compared to washes with 1x phosphate buffered saline (1x PBS) (pH 7.4). G-HCl eluent 398 
at pH 1.5 resulted in the most effective elution profile even after a single treatment exposure, 399 
with dissociation also observed at pH 2.0 and 3.0. The integrity of the VNAR protein and its 400 
re-binding functionality to SEED homodimer following exposure to eluents was tested by 401 
reapplying the homodimer protein post elution (Figure 7b).  402 
VNAR F3 functionalised streptavidin beads as SEED homodimer-specific capturing 403 
agents 404 
To further assess the potential application of VNAR F3 as a purification reagent, the lead 405 
candidate was biotinylated to facilitate immobilisation on a solid support. In order to avoid 406 
generation of heterogeneous products that may occur through chemical biotinylation, a site-407 
directed approach with a C-terminal Avi tag sequence, was used facilitating in vivo site-408 
directed biotinylation exploiting the E. coli biotin ligase (BirA).  409 
The ability to recover either SEED homodimer or heterodimer proteins from solution 410 
was determined using capture by streptavidin magnetic beads pre-decorated with biotinylated 411 
VNAR F3, and analysed via SDS-PAGE (Figure 8a). The streptavidin beads were heated in 412 
loading buffer to release the biotinylated protein from streptavidin prior to gel analysis. 413 
Consequently, some streptavidin was also released from the resin yielding a protein band 414 
migrating between 10 and 15 kDa. Specific capture of SEED homodimer from solution via 415 
bead-immobilised biotinylated-VNAR F3 was also evaluated by Western blot through 416 
detection of captured protein using an anti-human IgG (Fc specific)-HRP conjugate (Figure 417 
8b). 418 
Affinity enhancement through Fc reformatting 419 
One could imagine a situation where the lead F3 domain is used in certain instances as both an 420 
affinity capture reagent and a diagnostic (ELISA) reagent.  In an attempt to increase the 421 
functional affinity, and in turn the utility of the domain as a diagnostic tool, the VNAR F3 422 
monomer was reformatted as a mouse IgG2a Fc fusion construct, to generate a bivalent binder 423 
that should benefit from an avidity effect whilst at the same time offering an alternative 424 
immobilisation approach via Fc-capture. The VNAR F3-Fc was expressed transiently in a 425 
eukaryotic HEK293 system. Purification of the VNAR-fusion protein was achieved via protein 426 
A affinity chromatography using a suitable gravity-flow column. Protein quality was assessed 427 
via SDS-PAGE (Figure 9a) and indicated a highly purified VNAR F3-Fc with bands migrating 428 
between 40 kDa and 50 kDa, consistent with the predicted molecular weight. The concentration 429 
of the expressed protein was determined on an Ultrospec™ 6300 pro UV/Visible 430 
spectrophotometer (Amersham Bioscience, GE Healthcare) and confirmed a yield of 431 
approximately 4.5 mg per litre of cell culture. A small but noteworthy increase in apparent 432 
binding affinity, through an uplift in avidity (decreased off-rate), was achieved as kinetic 433 
assessment on the BIAcoreTM of the F3 monomer versus F3-Fc fusion resulted in a decrease in 434 
KD from 1.5 nM to 0.6 nM, using the SEED homodimer as an immobilised ligand (Table 2).  435 
No binding to heterodimer protein being observed (Figure 9b).    436 
The ability of the F3 lead to differentiate between SEED homodimer and heterodimer 437 
proteins in a heterogeneous solution mix was tested to determine the approximate limit of 438 
detection for the homodimer contaminant. The sandwich-based ELISA employed, 439 
demonstrated VNAR’s ability to specifically capture SEED homodimer in a concentration-440 
dependent manner from a heterogeneous mix of SEED proteins (Figure 10).  Increasing the 441 
heterodimer protein % did not contribute to the binding signal. The modest increase in affinity 442 
measure for the F3-Fc format did indeed appear to increase the sensitivity of this new reagent 443 
in an ELISA format with the bivalent F3-Fc capable of quantifying SEED homodimer 444 
contaminants in the mixture when they are only 2.5% of the total SEED protein, corresponding 445 
to 125 ng/mL.  446 
Applicability of VNAR F3 for target detection using bio-layer interferometry and surface 447 
plasmon resonance 448 
The VNAR F3-Fc fusion was assessed via bio-layer interferometry on an Octet® QK System 449 
(Pall FortéBio), testing its possible applicability as an “in-line” biosensor detection reagent 450 
with signal generated using anti-mouse IgG Fc capture. The immobilised VNAR-Fc construct 451 
demonstrated a concentration-dependent binding to SEED homodimer protein present in 452 
solution (Figure 11a). Surface plasmon resonance studies further validated the overall superior 453 
selectivity of the parental VNAR ligand as it was also able to detect and quantify the 454 
contaminating presence of SEED homodimer in a heterogeneous mixture of SEED proteins 455 
(Figure 11b). 456 
Discussion 457 
The central aim of this project was to explore the utility of shark-derived single domain binders 458 
as bioprocessing reagents, and in particular determine their ability to remove an important 459 
processing bottleneck in the development of “scaled-up” SEED bispecific therapeutics. The 460 
combination of shark-derived VNAR domains and phage-display is a well-trodden route to the 461 
successful isolation of specific binders to an ever-growing list of targets (Nuttall et al. 2001; 462 
Nuttall et al. 2002; Dooley et al. 2003; Liu et al. 2007; Liu, Anderson and Goldman 2007; 463 
Shao et al. 2007; Ubah et al. 2017). The potential applicability of camelid VHH single-domains 464 
as bioprocessing and affinity capture reagents (Detmers et al. 2010) and biosensors (Bever et 465 
al. 2016) have been previously reviewed.  Of particular relevance to this program of work, 466 
Klooster and colleagues (2007) isolated two IgG specific VHHs from an immune phage display 467 
library. These specifically recognised all four human IgG isotypes with nanomolar affinities 468 
(3–6 nM) through binding to the relatively conserved CH1 domain within the Fab region. This 469 
technology was subsequently commercialised under the name CaptureSelect™ IgG-CH1 470 
affinity matrix (Thermo Fischer Scientific) for human IgG purification, with a binding capacity 471 
of 25−30 g IgG/L (Kruljec and Bratkovič 2017).   GE Healthcare commercialised another 472 
camelid-based affinity ligand directed this time against the human constant domain of the λ 473 
light chain. This LambdaFabSelect affinity matrix was designed for Fab antibody fragment 474 
purification with a binding capacity of 12 g Fab/L.  475 
The growing list of commercially available VHH-based affinity resins sets the scene 476 
for the, as yet, unexplored application of shark-derived single-domains as bioprocessing 477 
reagents.  Whilst they share many similar properties with VHH domains at ∼11 kDa, VNARs 478 
are the smallest naturally occurring binding domains in the vertebrate kingdom (Stanfield et al. 479 
2004), and therefore possess a much  higher density of binding loops by size, with four regions 480 
of hypervariability contributing to  specificity (Kovaleva et al. 2014). Their small size 481 
combined with their amenability to modular reformatting and biomaterials conjugation 482 
(Kovaleva et al. 2014; Barelle and Porter 2015; Nogueira et al. 2019) offers the potential of 483 
multivalent arrangements for enhanced avidity as well as promoting high surface density 484 
formats leading to increased binding capacity.   485 
Interestingly, previous screens with scFv libraries failed to isolate binders capable of 486 
distinguishing between hetero and homodimer forms of the SEED protein (pers. commun., 487 
results not shown).  VHH libraries have not been screened, but their success with other IgG 488 
domains would suggest that they may also provide a source of discriminatory clones.   489 
The VNAR phage display library used as the starting material for this project was 490 
designed to contain extended CDR3 loops, ranging from 9–26 amino acids and typically longer 491 
than those found in the variable domains of mice or humans (Diaz et al. 2002).  In addition, 492 
the paratope of VNARs containing these extended CDRs appear pre-disposed to access 493 
pockets, grooves and protein clefts present on the surface of target proteins.  These cryptic 494 
epitopes (such as enzyme binding sites) (Stanfield et al. 2004), are rarely “seen” by more 495 
conventional antibodies which have a much more planar binding site, made up from variable 496 
heavy and light domains.  497 
Two requirements essential for the usefulness of an affinity ligand are: (i) binding 498 
specificity to target protein and (ii) effective elution of target from the ligand complex (with 499 
the possible added bonus of reusability) (Verheesen et al. 2003; Tu et al. 2015). VNARs were 500 
isolated using solution-phase selection techniques with biotinylated SEED homodimer protein 501 
captured on magnetic streptavidin beads. This solution-phase strategy was chosen to encourage 502 
the recognition of the soluble form of the SEED protein.  Four leads were specific for SEED 503 
homodimer and lacked reactivity to other Fc scaffolds (human, mouse, rat) including the SEED 504 
heterodimer.  505 
These results demonstrate VNAR’s exquisite ability to access and recognise differences 506 
between closely related and sterically restricted conformational epitopes most probably within 507 
the CH3-CH3 interface.  In the absence of a co-crystal structure, we can only speculate where 508 
this homodimer specific domain binds, but it is unlikely to be a linear peptide as this would 509 
tend to promote cross-reactivity with the heterodimeric (AG-GA) construct sharing the GA 510 
CH3 domain.  It is also unlikely that it binds outside of the SEED CH3 domain, such as the 511 
hinge region or the CH2 domain, as here again it is hard to see how discrimination between the 512 
two closely related proteins could be achieved.  It seems sensible to postulate that a 513 
combination of their reduced size and protruding CDR3 loop (average loop length of lead 514 
clones was 11 residues) enabled them to recognise the target molecule’s surface topology. 515 
Indeed, these characteristics of a VNAR paratope appears to predispose access to recessed 516 
epitopes otherwise intractable to the relatively flat binding surfaces of conventional mAbs 517 
(Stanfield et al. 2004; Stanfield et al. 2007; Henderson et al. 2007) as well as discontinuous 518 
anti-idiotypic epitopes (Könning, Rhiel et al. 2017).   With an average length of 11 amino acids 519 
the VNAR CDR3 loops of the lead clones are well within the CDR3 lengths seen in mammals, 520 
and so it might be sensible to conclude that the “finger-projection” positioning of the VNAR 521 
CDR3 may be even more important than simple loop length alone (Stanfield et al. 2004; 522 
Kovalenko et al. 2013). 523 
The affinity of this interaction was determined via surface plasmon resonance analysis 524 
on BIAcoreTM and one clone in particular, F3, had a single digit nanomolar affinity of 1.6 nM 525 
for homodimer and without measurable cross-reactivity to the closely related heterodimer 526 
protein. Whilst there are a few absolute affinities of VNARs reported in the literature, this high 527 
affinity was actually better than others previously published from a naïve spiny dogfish semi-528 
synthetic CDR3 mutagenised library of 10.2 ± 7.2 nM for staphylococcal enterotoxin B target 529 
(Liu, Anderson and Goldman 2007) and was closer to the sub-nanomolar affinity (0.7–0.9 nM) 530 
reported for a VNAR isolated from an immunised spiny dogfish-derived library against human 531 
serum albumin (Müller et al. 2012). This further emphasises the robustness of this non-532 
immunised synthetic VNAR phage display (combinatorial) platform, which combines the 533 
isolation of high affinity binders with a predisposition to recognise cryptic epitopes.   534 
One additional characteristic of the VNAR domains is their inherent ability to tolerate 535 
non-physiological (denaturing) conditions and again highlights their utility as a possible (and 536 
reusable) immunoaffinity reagent. IgNAR’s naturally reside in the harsh environment of shark 537 
serum consisting of high salt (1 osmolar) and high urea (350–500 mM) (Dooley et al. 2006; 538 
Stanfield et al. 2007; Trischitta et al. 2012). The F3 clone, in particular, retained functionality 539 
after overnight exposure to extremes of pH (pH 1.5–8.0) typically used for elution and 540 
regeneration of affinity resins (Verheesen et al. 2003; Wang et al. 2013), with retention of 541 
binding activity of 99.9 ± 1.4% and 92.4 ± 2% respectively.  542 
Similarly, clone F3 exhibited high thermal stability, retaining 55.6 ± 0.1% binding 543 
activity following 1 h incubation at 80oC and correlated well with previous stability 544 
assessments of VNARs (Dooley et al. 2003; Liu, Anderson and Goldman 2007; Goodchild et 545 
al. 2011), and VHH’s which has achieved <60% binding recovery after heat-induced unfolding 546 
in the range of 65–84°C (Dumoulin et al. 2002), and contrasted with conventional murine-547 
derived variable fragments and mAbs which were fully inactivated (irreversibly denatured) 548 
following 50oC and 70oC incubations, respectively (Goodchild et al. 2011).  Even after boiling 549 
at 100°C for 1 h, VNAR F3 retained 14.1 ± 1% binding activity to the SEED protein. VNAR 550 
protein architecture appears to encourage rapid refolding when returned to physiological 551 
conditions facilitated by their simple single-chain Ig structure, which unlike conventional 552 
antibodies presents a considerable number of exposed hydrophilic surface residues, as well as 553 
stabilising intra-molecular disulphide bridges (Stanfield et al. 2004; Streltsov et al. 2004).  554 
The VNAR’s apparent ability to selectively recognise SEED protein in solution 555 
indicates its potential as a sensitive and specific reagent for on-line diagnostic applications.  A 556 
capture assay using VNAR F3-functionalised magnetic beads showed VNAR’s applicability 557 
in this format. VNAR-Fc capture via anti-mouse IgG Fc capture Dip and Read™ biosensors in 558 
conjunction with bio-layer interferometry on the Octet® QK System further confirmed the 559 
functional interaction with the GA/GA SEED homodimer present in solution. This setup being 560 
an optimal Octet® format for screening cell culture supernatants with SEED protein free in 561 
solution, and functioning as a proof of concept of VNAR’s intended on-line application as a 562 
SEED homodimer detection reagent. 563 
Enhancement of binding reactivity of the single binding domain was achieved through 564 
multimerisation (Ubah et al. 2017), with dimerisation in the literature often resulting in as much 565 
as a 10-fold higher affinity than monomeric domains (Simmons et al. 2006). The homodimer 566 
specific VNAR F3 was reformatted as a mouse IgG2a Fc fusion, which allowed for 567 
dimerisation through Fc-mediated association whilst at the same time offering an alternative 568 
immobilisation approach via Fc-capture. The reformatted VNAR F3 domain demonstrated an 569 
enhanced affinity (KD) to 0.6 nM, and this was attributed to a modest avidity effect. This 2.5-570 
fold improvement over the parental monomeric construct was brought about by a 7.5-fold 571 
slower dissociation rate constant (kd). The enhanced affinity of the bivalent VNAR-reagent 572 
also translated into an improved sensitivity to target in a sandwich-based ELISA, and so whilst 573 
this delivered a relatively small enhancement in assay sensitivity from 500 ng/mL to 125 ng/mL 574 
for SEED homodimer protein detection, this could eventually be an important format for on-575 
line diagnostic applications.  576 
The VNAR F3 clone could also be used for affinity purification with regeneration of 577 
the reagent being an important and desirable property, and ideally comparable to protein A 578 
resin reusability of >100 purification cycles (Wang et al. 2013; Tu et al. 2015). The stability 579 
assessment data from these studies certainly confirmed VNAR’s ability to withstand overnight 580 
exposure to pH 1.5 without any detrimental effects in its binding capacity. The effect of eluent 581 
treatment on the VNAR’s integrity and ability to rebind SEED was assessed in an ELISA-582 
based elution assay, with a good stability profile observed following the first elution cycle.  583 
However, F3’s binding capacity was slowly diminished following consecutive cycles of elution 584 
at low pH range (1.5–2.0), but importantly stability was retained at pH 3.0, which is a typical 585 
elution condition used in affinity purification. No stripping of immobilised VNAR from the 586 
ELISA wells was detected, suggesting that its robustness and biological inactivity could make 587 
the VNAR ligand a superior and safer alternative to protein A, which has been associated with 588 
safety concerns related to stripping of protein A from columns and resulting risk of product 589 
contamination (Low et al. 2007). These initial findings imply that further optimisation, for 590 
instance by means of engineering pH-dependant binding through the generation of a histidine-591 
doped F3 sub-library (Könning et al. 2016) or the addition of a stress engineering step during 592 
the selection process for enhanced stability (Pershad and Kay 2013) may be desirable in a final 593 
product.  In a pH stability test designed to mimic the environment of the gut, comparing anti-594 
hTNF-α VNAR and VHH binding activity following exposure to pH 3.0 over extended periods, 595 
concluded that both domain scaffolds retained activity (around 80%) after 28 days.  This 596 
compared with a mAb which retained only 1.6% following 21 days exposure, when the 597 
experiment was stopped (Ubah et al. 2017).  598 
In conclusion, we have explored the utility of shark-derived single-domain VNARs as 599 
diagnostic and affinity reagents for targets that have proved intractable to more typical 600 
antibody-based technologies. Phage display selection was successful in delivering SEED 601 
homodimer specific VNAR domains with low nanomolar affinity, despite only subtle interface 602 
differences between SEED GA/GA and AG/GA heterodimer protein, with further affinity and 603 
sensitivity enhancement achieved upon dimerisation.  In addition, VNAR’s exceptional 604 
stability and resistance to irreversible denaturation marks VNAR domains as promising affinity 605 
capturing agents for a range of purification applications.  606 
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   729 
Fig. 1. Round specific monoclonal phage ELISA. (A) Monoclonal phage ELISA evaluating 92 730 
clones at each round of selection. Each point represents a single clone tested for binding to 731 
either the target SEED homodimer, or irrelevant control HSA. (B) Round 3 phage monoclonal 732 
ELISA assessing binding selectivity to SEED homodimer versus SEED heterodimer. Positive 733 
binders are defined as an absorbance 450 nm reading of ≥0.5. Relevant positive controls 734 
included: anti-HSA phage, anti-human IgG (Fc specific)-HRP antibody control for SEED 735 
coating. 736 
737 
Fig. 2. Sequence analysis of selected VNAR leads. (A) Amino acid sequence alignment 738 























































identity with the consensus (majority) sequence of the synthetic library backbone. Standard 740 
single letter amino acid nomenclature is employed. Relevant tags present: hexa-histidine tag - 741 
HHHHHH, c-Myc tag - EQKLISEEDL. (B) Ribbon representation of VNAR F3 domain 742 
generated via homology modelling using SWISS-MODEL and PyMOL software. VNAR F3 743 
domain modelled on PDB entry 4hgk (type IV short CDR3 loop) (Kovalenko et al. 2013). 744 
CDR1 and CDR3 loops, and the disulphide bond (S-S bond) formed between cysteine residues, 745 
are indicated. SWISS-MODEL accessed at http://swissmodel.expasy.org/ and PyMOL 746 
software (Schrödinger, Inc.). 747 
748 





homodimer versus binding to analogue Fc scaffolds: SEED heterodimer, human IgG and IgA 750 
from sera, and species cross reactivity to IgG from animal sera. Experiments were performed 751 
in duplicate, standard deviations are indicated. 752 
753 
Fig. 4. BIAcoreTM analysis of the F3 VNAR protein binding to SEED homodimer or 754 
heterodimer coated CM5 chip.  See Methods for protocol details. 755 
756 
Fig. 5. Sandwich ELISA determining the activity of immobilised VNAR proteins as capture 757 
reagents specific for SEED targets in solution. Either SEED homodimer (A) or SEED 758 
heterodimer (B). Experiments were performed in duplicate, standard deviations are indicated. 759 
 1 
 1 
A B              
 760 
 761 
Fig. 6. Stability analysis of VNAR F3 protein to resist irreversible denaturation in a range of 762 
physiological and non-physiological conditions. The % binding activity to SEED homodimer, 763 
with respect to an untreated homodimer control, was determined following incubation at a 764 
range of (A) pH and (B) temperatures. Experiments were performed in duplicate, standard 765 
deviations are indicated. (C) Thermal shift assays determining Tm of VNAR F3 (two separate 766 
protein expression batches). Melt peaks are shown for each individual VNAR on the first 767 
derivative plot of florescence data. Experiments were performed in triplicate. 768 
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769 
Fig. 7. ELISA-based elution assay comparing the effect of pH on elution efficiency. 770 
Absorbance values indicate relative amount of SEED homodimer bound to VNAR F3 771 
immobilised on an ELISA plate (A) upon application of eluents at various pH. Eluents were 772 
applied once, twice and three times. (B) Absorbance values indicate re-binding of immobilised 773 
VNAR F3 to SEED homodimer following multiple elutions at various pH. Experiments were 774 




Fig. 8. Assessing capture of SEED protein via biotinylated VNAR F3 immobilised on 777 
streptavidin magnetic beads. SEED protein - either homodimer (lane 1) or heterodimer (lane 778 
4) prior to depletion (control), depleted supernatant (lane 2 and 5 respectively) and VNAR-779 
functionalised streptavidin beads post-depletion (lane 3 and 6 respectively). (A) SDS-PAGE 780 
analysis of reduced samples detected with Coomassie staining. (B) Western blot analysis of 781 
reduced samples detected with anti-human IgG (Fc specific)-HRP conjugate. Protein marker: 782 
SpectraTM multicolour broad range protein ladder. 783 
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Fig. 9. Quality assessment of purified VNAR F3-Fc fusion. (A) SDS-PAGE of reduced 785 
samples, the VNAR F3-Fc fusion and a VNAR F3 monomer for comparison. (B) BIAcore™ 786 
T200 Sensorgrams of the VNAR F3-Fc fusion used to determine KD values via surface plasmon 787 




 A B 
790 
Fig. 10. Sandwich ELISA determining binding selectivity of the VNAR F3 monomer versus 791 
the F3-Fc fusion in a heterogeneous mix of SEED proteins in solution. SEED binding was 792 
detected with an anti-hIgG Fc-HRP. Experiments were performed in duplicate, standard 793 
deviations are indicated. 794 
 795 
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 798 
 Fig. 11. Binding assessment via bio-layer interferometry on the Octet® QK System (Pall 799 
FortéBio) and surface plasmon resonance on a BIAcore™ T200 System. (A) VNAR F3-Fc 800 
fusion capture via anti-mouse IgG Fc and the detection of SEED homodimer in solution, with 801 
concentration-dependent binding observed. (B) Surface plasmon resonance sensorgrams 802 
depicting binding between amine coupled VNAR F3 on the chip surface (at 200 RU) and its 803 
ability to recognise homodimer protein in a range of SEED protein mixtures. Response levels 804 
shown are with background values subtracted, and 0 RU marking the baseline.  805 
Table 1. Kinetic measurements of VNAR protein (analyte) binding to ligand SEED 806 
homodimer. Association (ka) and dissociation (kd) rate constants, and the equilibrium 807 
dissociation constants (KD) shown. No binding to SEED heterodimer was observed for any of 808 
the clones tested. 809 
Analyte ka (x 105 M-1 s-1) kd (x 10-4 s-1) KD (nM) 
F3 VNAR 2.3 3.7 1.6 
Analyte ka (x 105 M-1 s-1) kd (x 10-4 s-1) KD (nM) 
F3 VNAR 2.3 3.7 1.6 
E4 VNAR 2.6 5.6 2.1 
C3 VNAR 1.9 5.6 2.9 
A4 VNAR 0.4 7.9 21 















E4 VNAR 2.6 5.6 2.1 
C3 VNAR 1.9 5.6 2.9 
A4 VNAR 0.4 7.9 21 
 810 
Table 2. Kinetic measurements of VNAR F3 monomer versus F3-Fc fusion (dimer) binding to 811 
SEED homodimer ligand. Association (ka) and dissociation (kd) rate constants, and equilibrium 812 
dissociation constants (KD) shown. No binding to SEED heterodimer was observed (Figure 9). 813 
 814 
Analyte ka (x105 M-1 s-1) kd (x10-4 s-1) KD (nM) 
F3 monomer 1.9 3.0 1.5 
F3-Fc 0.7 0.4 0.6 
